结膜下注射地塞米松联合治疗急性原发性闭角型青光眼:一项随机对照试验
该随机对照试验纳入42例急性原发性闭角型青光眼患者,比较结膜下注射2.5 mg地塞米松联合常规治疗与单纯常规治疗的效果。结果显示注射组在24小时眼压显著低于对照组,总成功率79.7% vs 54.9%,且结膜红斑、睫状充血和疼痛严重程度更低。
要点
- 结膜下注射地塞米松可加速急性原发性闭角型青光眼高眼压的缓解。
- 24小时总成功率注射组79.7% vs 对照组54.9%(p=0.027)。
- 24小时结膜红斑、睫状充血和疼痛严重程度注射组低于对照组。
核心结论
- 结膜下注射地塞米松联合治疗急性原发性闭角型青光眼可显著加速高眼压的缓解,从而提高治疗成功率。
研究设计与样本
- 随机对照试验,共招募42例急性原发性闭角型青光眼患者,分为注射组21例和对照组21例。
主要发现
- 两组治疗后眼压均显著下降。
- 初始治疗后24小时,注射组眼压显著低于对照组(p=0.017)。
- Kaplan-Meier生存曲线分析显示,治疗后24小时总成功率注射组为79.7%,对照组为54.9%(p=0.027)。
- 治疗后24小时,注射组结膜红斑、睫状充血和疼痛的严重程度均低于对照组(p=0.012、p=0.048和p=0.013)。
- 两组在前房细胞、前房闪辉和畏光方面无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether the combined subconjunctival injection of dexamethasone can accelerate the decrease in intraocular pressure (IOP) in acute primary angle closure (APAC)-affected eyes. METHODS: 42 patients with APAC were recruited for a randomised controlled trial. These patients were separated into two groups: the injection group (21 patients) and the control group (21 patients). The injection group was subjected to a subconjunctival injection with 2.5 mg dexamethasone. Other drug treatments were the same with the control group. The follow-up was at 0, 3, 6, 12 and 24 hours after injection. The outcome measures include IOP and intraocular inflammation variables. RESULTS: The IOP was significantly decreased in both groups after treatment. However, 24 hours after the initial treatment, the IOP of the injection group was significantly lower compared with the control group (p = 0.017). Kaplan-Meier survival curve analysis showed that the total success rate of the injection group and the control group were 79.7% and 54.9% at 24 hours after treatment (p = 0.027), respectively. For the comparison of anterior chamber inflammation, the severity of conjunctival erythema, ciliary flush and pain in the injection group was also lower than that in the control group at 24 hours after treatment(p = 0.012, p = 0.048 and p = 0.013, respectively). No statistical significance was found between the two groups regarding the anterior chamber cells, anterior chamber flare and photophobia. CONCLUSION: The combined subconjunctival injection of dexamethasone for the management of APAC eyes can significantly accelerate the relief of high IOP, and therefore, improve the success rate of treatment.
引用
- Huang W, Li X, Gao K, et al. Combined subconjunctival injection of dexamethasone for the management of acute primary angle closure: a randomised controlled trial. Br J Ophthalmol. 2019. PMID: 31000508. doi:10.1136/bjophthalmol-2018-313473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。